梯瓦制药Teva Pharmaceutical Industries Limited (TEVA) 2004年年度报告「NYSE」.pdf

1、UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON,D.C.20549 FORM 20-F Or For the fiscal year ended December 31,2004 Or For the transition period from to Commission File number:0-16174 TEVA PHARMACEUTICAL INDUSTRIES LIMITED (Exact name of Registrant as specified in its charter)5 Basel Stree

2、t P.O.Box 3190 Petach Tikva 49131,Israel (Address of principal executive offices)Securities registered or to be registered pursuant to Section 12(b)of the Act:Securities registered or to be registered pursuant to Section 12(g)of the Act:American Depositary Shares(as evidenced by American Depositary

3、Receipts),each representing one Ordinary Share (Title of Class)Securities for which there is a reporting obligation pursuant to Section 15(d)of the Act:None?REGISTRATION STATEMENT PURSUANT TO SECTION 12(b)OR(g)OF THE SECURITIES EXCHANGE ACT OF 1934 ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d)OF THE

4、 SECURITIES EXCHANGE ACT OF 1934?TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d)OF THE SECURITIES EXCHANGE ACT OF 1934 N/A ISRAEL(Translation of Registrants name into English)(Jurisdiction of incorporation or organization)Title of each class Name of each exchange on which registeredNone None Indic

5、ate the number of outstanding shares of each of the issuers classes of capital or common stock as of the close of the period covered by the annual report.Indicate by check mark whether the registrant(1)has filed all reports required to be filed by Section 13 or 15(d)of the Securities Exchange Act of

6、 1934 during the preceding 12 months(or for such shorter period that the registrant was required to file such reports),and(2)has been subject to such filing requirements for the past 90 days.Yes No?Indicate by check mark which financial statement item the registrant has elected to follow.Item 17?Ite